XML 66 R47.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenues (Details) $ in Thousands |  |  |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 16, 2021 USD ($) | Jan. 28, 2021 EUR (€) | Jan. 08, 2018 | Mar. 31, 2015 USD ($) | Mar. 31, 2015 CAD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2022 CAD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2019 USD ($)
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Payments |  |  |  | $ 1,292 | $ 1,650 |  |  |  |
Additional payments (in Dollars) |  |  |  |  |  |  | $ 2,000 |  |
Payments percentage |  |  |  |  |  | 16.50% | 16.50% |  |
Up-front amount receive |  | € 250 |  |  |  | $ 3,000 |  |  |
Payables |  |  |  |  |  | 6,000 |  |  |
Amount received |  |  |  |  |  | 1,500 |  |  | $ 750
Additional and payments |  |  |  |  |  | 500 |  |  |
Distribution and supply agreement, description |  |  | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. |  |  |  |  |  |
Total payments |  |  |  |  |  | 750 |  |  |
Additional payments |  |  |  |  |  | $ 3,250 |  |  |
Royalties | 17.50% | 30.00% |  |  |  |  |  |  |
Signature date |  | 2 years |  |  |  |  |  |  |
Royalities, description |  | 15%-40% royalties on net sales upon regulatory approval for veterinary use. |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Cost plus percentage |  |  |  |  |  | 10.00% |  | 10.00% |
Maximum [Member] |  |  |  |  |  |  |  |  |
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Cost plus percentage |  |  |  |  |  | 23.00% |  | 23.00% |
Gebro Holding GmBH [Member] |  |  |  |  |  |  |  |  |
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Amount received |  |  |  |  |  | $ 1,850 |  | € 1,500,000 |
Additional and payments |  |  |  |  |  | 720 |  | € 600,000 |
CMS Medical Venture Investment Limited [Member] |  |  |  |  |  |  |  |  |
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Up-front amount receive |  |  |  |  |  | 2,000 |  |  |
Payables |  |  |  |  |  | 14,000 |  |  |
Amount received |  |  |  |  |  | 2,000 |  |  |
Milestone payments |  |  |  |  |  | 58,500 |  |  |
Ewopharma [Member] |  |  |  |  |  |  |  |  |
Revenues (Details) [Line Items] |  |  |  |  |  |  |  |  |
Up-front amount receive | $ 2,250 |  |  |  |  |  |  |  |
Payables | $ 40,450 |  |  |  |  |  |  |  |
Amount received |  |  |  |  |  | $ 2,250 |  |  |

X
- Definition The description of distribution and supply agreements. + References No definition available. + Details
Name: | canf_DistributionAndSupplyAgreementDescription
Namespace Prefix: | canf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of milestone. + References No definition available. + Details
Name: | canf_MilestonePercentage
Namespace Prefix: | canf_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | canf_RevenuesDetailsLineItems
Namespace Prefix: | canf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of royalities. + References No definition available. + Details
Name: | canf_RoyalitiesDescription
Namespace Prefix: | canf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The signature date. + References No definition available. + Details
Name: | canf_SignatureDate
Namespace Prefix: | canf_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4H -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959 + Details
Name: | us-gaap_AdditionalCollateralAggregateFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow to policyholder related to benefit payment for present value of total expected payment to policyholder in excess of present value of total expected assessment. Excludes benefit classified as market risk benefit or under provisions of Topic 815 on derivative and hedging. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 55 -Paragraph 13I -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441 + Details
Name: | us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AdditionalPaidInCapitalCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of regulatory assistance received from a federal regulatory agency in conjunction with either an acquisition of a troubled financial institution, transfer of nonperforming assets to a newly-formed entity, or other reorganization. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 11.N) -URI https://asc.fasb.org/extlink&oid=126897409&loc=d3e533348-122875 + Details
Name: | us-gaap_AmountOfRegulatoryAssistanceReceived1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred sale inducement cost capitalized on contract remaining in force. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 30 -Section 50 -Paragraph 2B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=6481654&loc=d3e11214-158414 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124505477&loc=d3e11332-158416 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(1) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641 + Details
Name: | us-gaap_DeferredSalesInducementsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of long-term loans payable classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878 + Details
Name: | us-gaap_OtherLoansPayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments of cash to suppliers for goods and services during the current period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585 + Details
Name: | us-gaap_PaymentsToSuppliers
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of FIFO (first in first out) inventory to total inventory as of the balance sheet date if other than 100 percent. + References No definition available. + Details
Name: | us-gaap_PercentageOfFIFOInventory
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 30 -Section 50 -Paragraph 1A -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729 + Details
Name: | us-gaap_SecuritiesReceivedAsCollateral
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of vesting of award under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=canf_GebroHoldingGmBHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalVentureInvestmentLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=canf_EwopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |